IPP-3 RT

What Is IPP-3 RT?

IPP-3 RT is a synthetic peptide and the first triple receptor agonist to reach phase 2 clinical investigation — simultaneously targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). This triple-axis pharmacology mechanistically distinguishes IPP-3 RT from every other incretin-class compound currently published in the literature, including dual GIP/GLP-1 agonists such as IPP-2 TRZ and GLP-1 single agonists such as IPP-1 SM.

Iron Peak Peptides supplies IPP-3 RT exclusively as a lyophilized research compound for licensed in vitro and preclinical in vivo laboratory use. All content on this page summarizes published scientific literature. This compound is not approved for human use and is not supplied for any clinical, compounding, or therapeutic purpose.

IPP-3 RT 10mg — Research Specifications

Triple Receptor Mechanism: GIP + GLP-1 + Glucagon Receptor Biology

IPP-3 RT's pharmacological signature derives from balanced agonism across three distinct class B GPCRs that each regulate separate but overlapping metabolic signaling pathways:

• GLP-1R (Glucagon-Like Peptide-1 Receptor): Expressed on pancreatic beta cells, hypothalamic neurons, and enteroendocrine cells. GLP-1R activation drives cAMP-mediated insulin secretion, suppresses glucagon release, and activates central satiety circuits via arcuate nucleus and vagal afferent signaling. GLP-1R agonism is the shared mechanistic anchor of the entire incretin peptide class.
• GIPR (GIP Receptor): Expressed on pancreatic beta cells, adipose tissue, and bone. GIPR co-activation in preclinical models has been associated with additive insulinotropic effects, enhanced adipose lipolysis signaling via adipocyte GIPR, and differential downstream phosphorylation profiles versus GLP-1R alone. Published in vitro work in GIPR-transfected HEK293 cells characterized distinct beta-arrestin recruitment kinetics versus GLP-1R activation.
• GCGR (Glucagon Receptor): Expressed primarily in hepatocytes. GCGR activation in isolation drives hepatic glucose output via cAMP-PKA signaling. Critically, published preclinical data demonstrates that GCGR agonism in the context of concurrent GLP-1R engagement produces net hepatic lipid mobilization without the hyperglycemic effect of isolated glucagon receptor stimulation — a mechanistic complementarity that makes the GLP-1R/GCGR pairing a productive area of metabolic pharmacology research.

The combination of all three receptor arms in a single molecule is what makes IPP-3 RT uniquely valuable as a research tool for dissecting incretin-glucagon axis biology — a research objective that cannot be cleanly accomplished with dual agonists or receptor-selective compounds alone.

Published Research: Phase 2 Clinical Data

A published phase 2 clinical investigation characterized IPP-3 RT's pharmacokinetics, receptor engagement dose-response relationships, and changes in metabolic biomarkers across dose cohorts in adult research participant cohorts over a 48-week observation period.

Key published findings include:

• Dose-dependent changes in body weight biomarkers across multiple once-weekly dose cohorts, with the highest dose cohort demonstrating mean changes not previously documented in any published incretin receptor agonist phase 2 trial at the time of publication
• Favorable tolerability profile consistent with GLP-1R agonist class effects (nausea, vomiting, decreased appetite), with dose-dependent incidence rates characterized across cohorts
• Changes in fasting plasma glucose, insulin, HbA1c, and lipid panel biomarkers documented alongside the primary weight-related endpoints
• No evidence of meaningful hepatotoxicity or cardiovascular safety signal over the 48-week observation window, supporting advancement to phase 3 evaluation

This dataset is now extensively cited in the academic incretin pharmacology literature as evidence of the mechanistic distinctiveness of triple GIP/GLP-1/GCG co-agonism versus dual-agonist or single-agonist approaches.

IPP-3 RT vs. IPP-2 TRZ vs. IPP-1 SM — Receptor Pharmacology Comparison

Preclinical Model Applications

IPP-3 RT has been investigated in multiple published preclinical model systems relevant to metabolic syndrome and hepatic lipid metabolism research:

• Diet-Induced Obese (DIO) C57BL/6 Mouse Models: Published preclinical data from early IPP-3 RT development studies characterized dose-dependent changes in body weight, adipose mass, insulin secretion kinetics, and hepatic glycogen content. Receptor-selective antagonist co-treatment experimental designs were used to attribute specific metabolic outcomes to individual receptor arms.
• Zucker Obese (fa/fa) Rat Models: Triple agonist administration in published Zucker rat studies documented changes in circulating lipid profiles and hepatic triglyceride content, with investigators distinguishing GCGR-mediated hepatic lipid oxidation contributions from GLP-1R-mediated insulin axis effects.
• NAFLD/NASH Hepatocyte Models: Primary hepatocyte cultures from NAFLD rodent models have been used to study GCGR-mediated changes in lipid oxidation enzyme expression, FGF21 secretion (a downstream glucagon signaling biomarker), and AMPK activation as a mechanistic intersection of GLP-1R and GCGR signaling.
• Receptor Knockout Comparative Studies: GLP-1R knockout and GCGR knockout mouse lines have been used in published investigations to isolate IPP-3 RT's receptor-specific pharmacological contributions — a research design only made possible by the compound's multi-receptor profile.
• In Vitro Receptor Binding Assays: GIPR-, GLP-1R-, and GCGR-transfected cell lines have been used in competitive radioligand binding studies to characterize IPP-3 RT's receptor affinity profile, EC50 values, and relative activation potency at each receptor target.

Storage, Handling & Reconstitution (Research Reference)

For a detailed chemistry reference, see the Iron Peak Peptides Peptide Reconstitution Guide.

How to Interpret the IPP-3 RT Evidence

IPP-3 RT research spans receptor pharmacology, animal models, and controlled human trials. Those evidence types answer different questions: cell and animal studies help examine mechanism, while clinical studies report findings within their specific enrolled populations, protocols, and observation periods. Findings from one setting should not be treated as interchangeable with findings from another.

For a disciplined literature review, researchers can distinguish the compound's three-receptor profile from outcome claims, check the study design and duration, and note what the investigators actually measured. IPP-3 RT remains an active area of research; further evidence and longer-term data may refine the published picture. This page is a research reference only and does not provide medical, clinical, or dosing guidance.

For adjacent pathway comparisons, see IPP-2 TRZ 10mg (dual GIP/GLP-1 agonism) and IPP-1 SM (GLP-1 agonism).

Purity, Quality Assurance & quality assurance documentation

Iron Peak Peptides supplies IPP-3 RT at ≥99% purity, HPLC-verified with UV detection. Each production lot undergoes:

• HPLC purity trace — chromatographic purity confirmation ≥99%
• Mass spectrometry (MS) — molecular identity and sequence integrity confirmation
• Endotoxin testing — LAL method, reported in EU/mg, relevant for in vivo rodent research applications
• Residual solvent analysis — documented per lot, consistent with in vitro receptor binding and cell-based assay requirements

quality assurance documentation documentation is available for every lot. Contact info@ironpeakpeptides.com with your order number to request quality documentation documentation.

Related Research Compounds

Researchers building multi-compound metabolic signaling protocols may also reference:

• IPP-2 TRZ 10mg — dual GIP/GLP-1 agonist; published phase 3 data; ideal for head-to-head dual vs. triple agonism research designs
• IPP-1 SM — GLP-1 single agonist; the established GLP-1R reference standard for incretin pathway comparisons
• Metabolic Research Stack — curated multi-compound protocol bundle featuring complementary metabolic signaling peptides
• BPC-157 10mg — tissue repair peptide investigated in published GI and musculoskeletal regeneration models

Frequently Asked Questions — IPP-3 RT Research Peptide

What is IPP-3 RT?

IPP-3 RT is a synthetic 39-residue acylated peptide and the first triple receptor agonist to be investigated in phase 2 clinical research. It simultaneously activates three distinct class B GPCRs: the GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). It is supplied by Iron Peak Peptides as a lyophilized research compound for laboratory use only — not for human use.

How does IPP-3 RT work?

IPP-3 RT works by binding to and activating three receptors that regulate overlapping metabolic pathways. GLP-1R activation drives cAMP-mediated insulin secretion and central satiety signaling. GIPR engagement adds additive insulinotropic and adipose lipolysis signaling effects. GCGR activation triggers hepatic lipid mobilization via cAMP-PKA, which in the context of co-activated GLP-1R does not produce the isolated hyperglycemia associated with pure glucagon receptor stimulation. The combined triple-receptor engagement is the subject of active academic research into synergistic incretin-glucagon axis biology.

What is the difference between IPP-3 RT and IPP-2 TRZ?

IPP-2 TRZ is a dual GIP/GLP-1 receptor agonist — it targets two receptors (GIPR + GLP-1R). IPP-3 RT is a triple agonist — it adds glucagon receptor (GCGR) activation to the dual-agonist base. The addition of GCGR engagement introduces a hepatic lipid oxidation signaling component not present in IPP-2 TRZ's pharmacological profile, making the two compounds mechanistically distinct research tools despite sharing GIPR and GLP-1R activity. Iron Peak Peptides offers IPP-2 TRZ 10mg for direct comparative research.

What is the difference between IPP-3 RT and IPP-1 SM?

IPP-1 SM is a GLP-1 single agonist targeting only GLP-1R. IPP-3 RT is a triple agonist targeting GLP-1R, GIPR, and GCGR simultaneously. The two compounds share GLP-1R as a common target but diverge completely in GIPR and GCGR engagement, making IPP-1 SM the appropriate single-receptor reference standard in experimental designs where GLP-1R-specific effects need to be isolated from the triple-agonist pharmacology.

What did the published phase 2 IPP-3 RT study find?

A published phase 2 clinical trial characterized IPP-3 RT's dose-response pharmacokinetics and changes in metabolic biomarkers across dose cohorts in adult research participant cohorts. The study documented dose-dependent changes in body weight biomarkers at 48 weeks across the 1mg, 4mg, 8mg, and 12mg cohorts, with the highest-dose cohort results representing the largest mean weight-related changes published in any incretin receptor agonist phase 2 trial at the time. The study also characterized GI tolerability profiles and documented changes in fasting glucose, HbA1c, insulin, and lipid panel biomarkers.

What receptors does IPP-3 RT target?

IPP-3 RT targets three class B G-protein coupled receptors: (1) the glucagon-like peptide-1 receptor (GLP-1R), (2) the glucose-dependent insulinotropic polypeptide receptor (GIPR), and (3) the glucagon receptor (GCGR). This triple-receptor profile is what distinguishes it from all other published incretin-class peptides.

What is the CAS number for IPP-3 RT?

IPP-3 RT is catalogued under CAS number 2381706-06-3. Iron Peak Peptides supplies IPP-3 RT strictly as a research compound for preclinical and in vitro laboratory use in licensed research settings. It is not supplied for any human, compounding, or therapeutic application.

What is the molecular weight of IPP-3 RT?

IPP-3 RT has a molecular weight of approximately 4,771 Da. It is a 39-residue acylated chimeric peptide derived from native GIP, GLP-1, and glucagon sequences, with C18 fatty acid acylation to extend its half-life consistent with once-weekly dosing in published clinical pharmacokinetics studies.

What purity is research-grade IPP-3 RT?

Iron Peak Peptides supplies IPP-3 RT at ≥99% HPLC-verified purity with mass spectrometry confirmation of molecular identity. Each lot includes quality assurance documentation documentation covering purity trace, endotoxin parameters, and residual solvent analysis appropriate for in vitro and in vivo preclinical research applications.

How should IPP-3 RT be stored?

Unreconstituted lyophilized IPP-3 RT should be stored at -20°C, protected from light and moisture, for up to 24 months. Once reconstituted, store at 4°C and use within 28 days. Do not refreeze reconstituted solution. See the Iron Peak Peptides Peptide Reconstitution Guide for full handling protocol.

What animal models is IPP-3 RT used in?

Published preclinical IPP-3 RT investigations have used diet-induced obese (DIO) C57BL/6 mice, Zucker obese (fa/fa) rats, primary hepatocyte cultures from NAFLD models, and receptor knockout mouse lines (GLP-1R KO, GCGR KO). In vitro assay systems have included GIPR-, GLP-1R-, and GCGR-transfected cell lines for competitive radioligand binding and cAMP-response assays.

For Research Purposes Only. Not for human consumption. This product is intended exclusively for use in licensed research laboratory settings. Iron Peak Peptides does not supply IPP-3 RT for any compounding, clinical, or therapeutic application. All content on this page references published scientific literature only.